Related Experiment Video

Updated: Aug 5, 2025

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.2K

Novel Insights into RAD52's Structure, Function, and Druggability for Synthetic Lethality and Innovative Anticancer

Beatrice Balboni1,2, Francesco Rinaldi1,2, Viola Previtali1

  • 1Computational and Chemical Biology, Istituto Italiano di Tecnologia, via Morego 30, 16163 Genoa, Italy.

Cancers
|March 29, 2023
PubMed

Insights

The RAD52 protein is a key player in DNA repair and a promising drug target for cancer. Inhibiting RAD52 shows synthetic lethality in specific cancer cells, highlighting its therapeutic potential.

Area of Science:

  • Molecular Biology
  • Genetics
  • Cancer Research

Background:

  • RAD52 protein is a mediator of DNA repair pathways.
  • RAD52 inhibition is synthetically lethal in cancers with homologous recombination defects.
  • RAD52 is an emerging pharmacological target for cancer therapy.

Purpose of the Study:

  • To comprehensively review structural and functional information on RAD52.
  • To highlight pathways involving RAD52 and inhibition strategies.
  • To discuss the complex role and structural arrangement of RAD52.

Main Methods:

  • Literature review of structural and functional data on RAD52.
  • Analysis of RAD52's role in DNA repair pathways.
  • Exploration of RAD52 inhibition approaches.

Main Results:

  • RAD52's multifaceted role in DNA repair is detailed.
  • Complex structural dynamics of RAD52 are presented.
  • Synthetic lethality of RAD52 inhibition in specific cancer contexts is discussed.

Conclusions:

  • RAD52 is a critical target for cancer drug discovery.
  • Further research into RAD52's complex mechanisms is needed.
  • Understanding RAD52's structure and function will advance therapeutic strategies.
Keywords:
RAD52drug discoveryprecision medicinesynthetic lethality

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

506
Author Spotlight: Unveiling the Role of SNF2L in Replication Fork Stability and Genome Duplication05:55

Author Spotlight: Unveiling the Role of SNF2L in Replication Fork Stability and Genome Duplication

Published on: August 23, 2024

585

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Restarting Stalled Replication Forks02:37

Restarting Stalled Replication Forks

DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart,...
5.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K